PRODUCT INFORMATION

ARRY-382

Item No. 38796

CAS Registry No.:	1313407-95-2
Formal Name:	N-[3-cyclopropyl-1-[(6-methyl-2-pyridinyl)methyl]-1H-indazol-4-yl]-7-[2-(4-methyl-1-piperazinyl)ethoxy]-imidazo[1,2-a]pyridine-3-carboxamide
MF:	$C_{32}H_{36}N_8O_2$
FW:	564.7
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ARRY-382 is supplied as a solid. A stock solution may be made by dissolving the ARRY-382 in the solvent of choice, which should be purged with an inert gas. ARRY-382 is soluble in acetonitrile and DMSO.

Description

ARRY-382 is an inhibitor of the colony-stimulating factor 1 receptor (CSF1R; IC_{50} = 9 nM).[1] It is selective for CSF1R over PDGFR, c-Kit, and FMS-related tyrosine kinase 3 (FLT3; IC_{50}s = >10,000 nM for all). ARRY-382 (10 µM) induces apoptosis in several primary human chronic lymphocytic leukemia (CLL) cell lines. It also enhances the cytotoxicity of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (Item No. 16274) and PI3K p110δ inhibitor idelalisib (CAL-101; Item No. 15279) in several primary human CLL cell lines when used at concentrations ranging from 0.15625 to 10 µM.

Reference

1. Edwards D.K., V., Sweeney, D.T., Ho, H., *et al.* Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. *Oncotarget* **9(37)**, 24576-24589 (2018).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM